文献速递头颈外科

重新审视RTOG 1221假说:III/IV期HPV阴性口咽癌的治疗

Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer.
PubMed 文献 · Otolaryngol Head Neck Surg · 2020-11-17

本研究基于美国国家癌症数据库(2010-2016年,3004例)和SEER数据库(670例)进行回顾性队列研究,探讨cT1-2N1-2bM0 HPV阴性口咽鳞癌中首选手术联合风险适应性辅助治疗是否优于单纯放化疗。加权多变量Cox回归显示,推荐首选手术者总生存优于推荐单纯放化疗者(HR 0.77,95%CI 0.68-0.86);SEER队列中推荐手术者总生存(HR 0.69,95%CI 0.54-0.87)和头颈癌特异性生存(HR 0.59,95%CI 0.41-0.84)均更优。结论支持对cT1-2N1-2bM0 HPV阴性口咽癌采用手术联合风险适应性辅助治疗。

要点

  • 推荐首选手术较单纯放化疗改善总生存(HR 0.77,95%CI 0.68-0.86)。
  • 实际接受手术联合辅助放化疗者总生存更优(HR 0.59,95%CI 0.50-0.71)。
  • SEER队列证实手术推荐与总生存及头颈癌特异性生存改善相关。

核心结论

  • 研究结果支持对cT1-2N1-2bM0 HPV阴性口咽癌采用手术联合风险适应性辅助治疗。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库(3004例)和SEER数据库(670例)2010-2016年数据。
  • 统计方法包括Kaplan-Meier生存分析、logistic回归、Cox比例风险回归及逆倾向评分加权。

主要发现

  • 加权多变量Cox回归显示,推荐首选手术者较推荐单纯放化疗者总生存改善(HR 0.77,95%CI 0.68-0.86)。
  • 基于实际接受治疗的事后多变量分析显示,手术联合辅助放化疗较单纯放化疗改善总生存(HR 0.59,95%CI 0.50-0.71)。
  • SEER队列中,推荐首选手术者较单纯放化疗者总生存改善(HR 0.69,95%CI 0.54-0.87),头颈癌特异性生存改善(HR 0.59,95%CI 0.41-0.84)。

临床怎么用

  • 对于cT1-2N1-2bM0 HPV阴性口咽癌,可考虑首选手术并根据风险添加辅助治疗。

局限性

  • 为回顾性研究,非随机对照试验,存在选择偏倚等固有局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In 2014, the Radiation Therapy Oncology Group 1221 trial was initiated to analyze whether surgery with risk-based radiation therapy or chemoradiation therapy was superior to chemoradiation therapy alone in patients with clinically staged T1-2N1-2bM0 HPV-negative oropharyngeal squamous cell carcinoma. However, the study was prematurely terminated. Given the lack of a randomized controlled trial, we retrospectively approached the same question using large national cancer databases. STUDY DESIGN: Retrospective cohort study. SETTING: The National Cancer Database and Surveillance, Epidemiology, and End Results (SEER) program from 2010 to 2016. METHODS: We identified 3004 patients in the National Cancer Database and 670 patients in the SEER database. Statistical techniques included Kaplan-Meier survival analysis, binary and multinomial logistic regressions, Cox proportional hazard regressions, and inverse propensity score weighting. RESULTS: On weighted multivariable Cox regression, patients recommended to receive frontline surgery had improved overall survival as compared with those recommended to receive chemoradiation therapy alone (hazard ratio [HR], 0.77; 95% CI, 0.68-0.86). On post hoc multivariable analysis based on therapy actually received, frontline surgery with adjuvant chemoradiation therapy was associated with improved overall survival (HR, 0.59; 95% CI, 0.50-0.71) as compared with chemoradiation therapy without surgery. Analysis of the SEER cohort revealed improved overall survival (HR, 0.69; 95% CI, 0.54-0.87) and head and neck cancer-specific survival (HR, 0.59; 95% CI, 0.41-0.84) in patients recommended to receive frontline surgery over chemoradiation therapy alone. CONCLUSION: Our findings support the use of surgery with risk-based addition of adjuvant therapy in patients with cT1-2N1-2bM0 HPV-negative oropharyngeal cancer.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Jacobs D, Torabi SJ, Park HS, et al. Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer. Otolaryngol Head Neck Surg. 2020. PMID: 33198564. doi:10.1177/0194599820969613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。